4149 related articles for article (PubMed ID: 6881976)
21. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
Gajewski TF; Fallarino F; Ashikari A; Sherman M
Clin Cancer Res; 2001 Mar; 7(3 Suppl):895s-901s. PubMed ID: 11300489
[TBL] [Abstract][Full Text] [Related]
22. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
24. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
25. Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man.
Irie RF; Giuliano AE; Morton DL
J Natl Cancer Inst; 1979 Aug; 63(2):367-73. PubMed ID: 88539
[TBL] [Abstract][Full Text] [Related]
26. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
27. Shared antigens between human malignant melanoma cells and Mycobacterium bovis (BCG).
Minden P; Sharpton TR; McClatchy JK
J Immunol; 1976 May; 116(5):1407-14. PubMed ID: 58033
[TBL] [Abstract][Full Text] [Related]
28. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells.
Savage HE; Rossen RD; Hersh EM; Freedman RS; Bowen JM; Plager C
Cancer Res; 1986 Apr; 46(4 Pt 2):2127-33. PubMed ID: 3948184
[TBL] [Abstract][Full Text] [Related]
29. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
30. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen.
Jones PC; Sze LL; Liu PY; Morton DL; Irie RF
J Natl Cancer Inst; 1981 Feb; 66(2):249-54. PubMed ID: 6935475
[TBL] [Abstract][Full Text] [Related]
31. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
33. Increased ovarian tumor cell surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate treatment.
Ioannides CG; Platsoucas CD; Bowen JM; Wharton JT; Freedman RS
Anticancer Res; 1989; 9(1):81-6. PubMed ID: 2705759
[TBL] [Abstract][Full Text] [Related]
34. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
[TBL] [Abstract][Full Text] [Related]
35. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
36. Changes in distribution of human malignant melanoma membrane antigens in the presence of human antibody by immunofluorescence.
Leong SP; Sutherland CM; Krementz ET
Cancer Res; 1977 Jan; 37(1):293-8. PubMed ID: 318607
[TBL] [Abstract][Full Text] [Related]
37. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Carey TE; Takahashi T; Resnick LA; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3278-82. PubMed ID: 1067619
[TBL] [Abstract][Full Text] [Related]
38. Production of antisera with specificity for malignant melanoma and human fetal skin.
Fritze D; Kern DH; Drogemuller CR; Pilch YH
Cancer Res; 1976 Feb; 36(2 Pt 1):458-66. PubMed ID: 56991
[TBL] [Abstract][Full Text] [Related]
39. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
40. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL
Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
